Vimarsana
Biggest News Aggregation in the World

Page 7 - Susan Ringdal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Susan Ringdal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Susan Ringdal Today - Breaking & Trending Today

Hikma resumes launch of generic Advair Diskus® - Vimarsana News

Hikma resumes launch of generic Advair Diskus®

Hikma resumes launch of generic Advair Diskus® News provided by Share this article Share this article LONDON, April 20, 2021 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that it has resumed the launch of its generic version of GlaxoSmithKline's Advair Diskus ®1 in the US following US FDA approval of an amendment Hikma submitted to its Abbreviated New Drug Application in January 2021. The amendment reflected enhanced packaging controls to meet new industry standards adopted since the initial submission of its ANDA.  Hikma will imm...

Investegate |Hikma Pharmaceutical Announcements | Hikma Pharmaceutical: Director/PDMR Shareholding - Vimarsana News

Investegate |Hikma Pharmaceutical Announcements | Hikma Pharmaceutical: Director/PDMR Shareholding

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional bod...

Investegate |Hikma Pharmaceutical Announcements | Hikma Pharmaceutical: Notice of Results - Vimarsana News

Investegate |Hikma Pharmaceutical Announcements | Hikma Pharmaceutical: Notice of Results

Camilla Cunningham  + 44 (0) 7464 982426   About Hikma Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable Moody's) Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East ...

Investegate |Hikma Pharmaceutical Announcements | Hikma Pharmaceutical: Potential Acquisition - Vimarsana News

Investegate |Hikma Pharmaceutical Announcements | Hikma Pharmaceutical: Potential Acquisition

About Hikma Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI: 549300BNS685UXH4JI75) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable Moody's)   Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europ...

Hikma launches generic Advair Diskus® following FDA approval - Vimarsana News

Hikma launches generic Advair Diskus® following FDA approval

Hikma launches generic Advair Diskus® following FDA approval News provided by Share this article Share this article LONDON, Dec. 17, 2020 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has received FDA approval for and launched its generic version of GlaxoSmithKline's Advair Diskus ®1 (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US. Hikma worked with Vectura Group, a UK based provider of innovative inhaler drug delivery solutions, to develop the proprietary dry powder...